Table 2. Mitotic count and survival.
|
Overall survival (%) |
Event-free survival (%) |
||||||
|---|---|---|---|---|---|---|---|
| No. of patients | 5 years | s.e. | P (log-rank) | 5 years | s.e. | P (log-rank) | |
|
Mitotic count before SC | |||||||
| Low (1–9/10 HPF) | 7 | 66.7 | 19.2 | 0.551 | 71.4 | 17.1 | 0.399 |
| Intermediate (10–19/10 HPF) | 8 | 85.7 | 13.2 | 0.156 | 46.9 | 18.7 | 0.845 |
| High (⩾20/10 HPF) | 17 | 62.9 | 13.8 | 52.2 | 13.5 | ||
| Low vs high | 0.549 | 0.411 | |||||
|
Mitotic count after SC | |||||||
| Low (1–9/10 HPF) | 28 | 86.1 | 7.5 | 0.886 | 66.5 | 10.0 | 0.346 |
| Intermediate (10–19/10 HPF) | 14 | 76.9 | 15.3 | 0.017 | 53.1 | 14.1 | 0.213 |
| High (⩾20/10 HPF) | 15 | 33.3 | 13.9 | 40.0 | 12.6 | ||
| Low vs high | 0.001 | 0.016 | |||||
| Low+intermediate vs high | <0.001 | 0.019 | |||||
Abbreviations: HPF=high power fields; SC=systemic chemotherapy; s.e.=standard error.